Anteris Technologies (ASX:AVR) recently presented new patient data at the TVT conference showing that DurAVR THV maintained positive haemodynamic performance at 30 days, as reported with this patient cohort at 48 hours post-procedure.
The preliminary results comprised the latest seven patients enrolled in the DurAVR First-In-Human Study, with all achieving implant success with no device-related complications.
According to CEO Wayne Paterson, “The results from the latest seven patients signal that DurAVR THV continues to perform well in small annulus sizes.
“We saw greater haemodynamic improvement in these difficult-to-treat patients, and this encouraging data continues to support the thesis that DurAVR THV, a new class of biomimetic valve, will be an important treatment option for patients in the future.”
